Xtant Medical Stock Price, News & Analysis

Xtant Medical (NYSE American: XTNT) reported strong Q1 2025 financial results with revenue increasing 18% year-over-year to $32.9 million. The company achieved positive net income of $58,000, compared to a net loss of $4.4 million in Q1 2024. Key highlights include gross margin of 61.5%, Adjusted EBITDA of $3.0 million, and positive operating cash flow of $1.3 million. The growth was primarily driven by increased orthobiologics sales and licensing revenue. Xtant recently launched Trivium™, a next-generation demineralized bone matrix allograft, and completed a secondary private sale of shares by OrbiMed Advisors. Based on strong performance, the company increased its 2025 revenue guidance to $127-131 million, representing 8-12% growth.

Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal, orthopedic, and woundcare disorders, has scheduled its first quarter 2025 financial results announcement for May 12, 2025, after market close.

The company will host a conference call at 4:30 PM ET on the same day, featuring President and CEO Sean Browne and CFO Scott Neils. Investors can access the call via domestic (888-506-0062) or international (973-528-0011) dial-in numbers using passcode 828748. A webcast replay will be available on the company's website afterward.

Xtant Medical Holdings (NYSE American: XTNT) has launched Trivium™, a next-generation demineralized bone matrix (DBM) allograft featuring advanced PureLoc™ Fiber Technology. The product combines three synergistic elements for enhanced structure, handling, and biological activity.

Trivium's unique design includes intertwined structures and interconnected porosity to support cell attachment and tissue ingrowth. The product utilizes Xtant's proprietary BacteRinse® processing method, which has been clinically proven to preserve bone morphogenetic proteins (BMPs) over two decades.

The new bone graft offers superior moldability for precise placement across various surgical applications and is now available through the company's nationwide network of independent agents.

Xtant Medical Holdings (NYSE: XTNT) announced a significant ownership transition as OrbiMed Advisors completed a secondary private sale of 73.1 million shares to several investors, led by Nantahala Capital Management. The transaction terminated OrbiMed's investor rights agreement, providing Xtant greater strategic flexibility.

The company revealed preliminary Q1 2025 revenue expectations of $32.8-33.1 million, representing an 18-19% growth compared to Q1 2024, driven by orthobiologics and licensing revenue. Management emphasized their strategy to prioritize profitability through focusing on higher-margin orthobiologics and leveraging their Montana manufacturing facility for operational efficiencies.

While Xtant received no proceeds from the transaction, the company agreed to register the resale of shares on Form S-1 with the SEC. The company plans several new product launches to expand beyond spine applications in 2025.

Xtant Medical (NYSE:XTNT) reported strong Q4 and full-year 2024 results, with annual revenue growing 28% to $117.3 million. Q4 revenue increased 12% year-over-year to $31.5 million, driven by biologics product growth.

The company's gross margin decreased to 50.8% in Q4 2024 from 61.0% in Q4 2023, while full-year margin dropped to 58.2% from 60.8%. Net loss for 2024 was $16.4 million compared to net income of $660,000 in 2023.

Key developments include a new manufacturing agreement worth $1.5 million upfront, $5 million in cost reductions, and projected 2025 revenue guidance of $126-130 million. Management expects to generate free cash flow in H2 2025 without requiring additional external capital.

Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in spinal disorder treatments, has scheduled its Fourth Quarter and Year End 2024 financial results announcement for March 6, 2025, after market close.

The company will host a conference call at 4:30 PM ET on the same day, featuring President and CEO Sean Browne and CFO Scott Neils. Investors can access the call via domestic (888-506-0062) or international (973-528-0011) dial-in numbers using passcode 907938. A webcast will be available, with a replay accessible later on the company's website.

Xtant Medical reported Q3 2024 financial results with revenue of $27.9 million, up 12% year-over-year, and year-to-date revenue of $85.8 million, up 36%. The company posted a net loss of $5.0 million compared to net income of $9.2 million in Q3 2023. Gross margin decreased to 58.4% from 61.3%. Notable developments include launching OsteoVive+ and Cortera Posterior Fixation System, signing a license agreement worth minimum $5.25 million, and completing a $5.0 million private placement. The company reaffirmed its full-year 2024 revenue guidance of $116-120 million, representing 27-31% growth.

Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in spinal disorder treatments, has announced its participation in the 15th Annual Craig-Hallum Alpha Select Conference. The event will take place on November 19, 2024, at the Sheraton NY Times Square Hotel in New York City. CEO Sean Browne and CFO Scott Neils will represent the company in one-on-one meetings during the conference.

Xtant Medical Holdings (NYSE American: XTNT) announced it will release its third quarter 2024 financial results on November 12, 2024, after market close. The company will host a conference call at 4:30 PM ET the same day, featuring President and CEO Sean Browne and CFO Scott Neils. The call will be accessible via phone and webcast, with a replay available on the company's website afterward.